Onelax

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the relief of occasional constipation (irregularity). It generally produces a bowel movement within 0.5 to 6 hours after administration.

Dosage and Administration

Patients should consume a full glass (8 ounces) of liquid with each dose. The medication may be administered as a single daily dose or divided into multiple doses throughout the day.

For adults and children aged 12 years and older, the recommended dosage ranges from 1/2 bottle to 1 bottle (10 fl oz). For children aged 6 to 11 years, the appropriate dosage is between 1/3 bottle to 1/2 bottle.

For children under 6 years of age, it is advised to consult a healthcare professional for appropriate dosing recommendations.

Contraindications

Laxative products are contraindicated for use beyond one week unless directed by a healthcare professional. Prolonged use may lead to dependency or other adverse effects. Additionally, exceeding the maximum recommended daily dosage within a 24-hour period is contraindicated due to the potential for serious side effects and complications.

Warnings and Precautions

The use of laxative products requires careful consideration to ensure patient safety and efficacy. It is imperative that these products are not utilized for longer than one week unless specifically directed by a healthcare professional.

Healthcare providers should advise patients to consult a physician prior to use if they have any of the following conditions: kidney disease, a magnesium-restricted diet, a sodium-restricted diet, stomach pain, nausea, or vomiting. Additionally, patients who have experienced a sudden change in bowel habits lasting more than one week should seek medical advice before using laxatives.

Patients currently taking prescription medications should also be encouraged to discuss their use of laxative products with a doctor or pharmacist to avoid potential drug interactions.

While using laxative products, it is crucial that patients adhere to the maximum recommended daily dosage within a 24-hour period. Exceeding this dosage can lead to adverse effects.

Patients must be instructed to discontinue use and consult a healthcare professional if they experience rectal bleeding or if there is no bowel movement following the use of the product, as these symptoms may indicate a serious underlying condition.

In the event of an overdose, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this product. Serious adverse reactions may include rectal bleeding or the absence of bowel movement after use, which could indicate a serious underlying condition. In such cases, patients are advised to stop use and consult a healthcare professional immediately.

Before using this product, patients should seek medical advice if they have a history of kidney disease, are on a magnesium-restricted or sodium-restricted diet, are experiencing stomach pain, nausea, or vomiting, or have noticed a sudden change in bowel habits lasting more than one week.

It is important to note that laxative products should not be used for longer than one week unless directed by a healthcare provider. Patients should also adhere to the maximum recommended daily dosage within a 24-hour period to avoid potential complications.

For pregnant or breastfeeding individuals, consultation with a healthcare professional is recommended prior to use. In the event of an overdose, patients should seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222.

Drug Interactions

There are currently no documented drug interactions or interactions with laboratory tests associated with this medication. As such, no specific recommendations for dosage adjustments or monitoring are necessary at this time. Healthcare professionals should continue to assess individual patient circumstances and consider any potential interactions based on the patient's overall medication regimen.

Packaging & NDC

Below are the non-prescription pack sizes of Onelax (magnesium citrate). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 12 years and over may be administered 1/2 bottle to 1 bottle (10 fl oz). For children aged 6 to 11 years, the recommended dosage is 1/3 bottle to 1/2 bottle. It is advised that children under 6 years of age consult a doctor prior to use.

Healthcare professionals should ensure that the product is kept out of reach of children. In the event of an overdose, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure the safety of both the mother and the developing fetus.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment should consult a healthcare professional prior to use, particularly if they have a history of kidney disease. It is essential to assess renal function and consider potential dosing adjustments or monitoring requirements based on the degree of impairment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdose, it is imperative to seek immediate medical assistance. Healthcare professionals should advise patients or caregivers to contact a Poison Control Center at 1-800-222-1222 without delay. Prompt intervention is crucial to mitigate potential adverse effects associated with overdose.

Symptoms of overdose may vary depending on the specific substance involved; therefore, a thorough assessment and monitoring of the patient are essential. Healthcare providers should be prepared to manage any symptoms that may arise and provide supportive care as necessary.

Management of an overdose typically involves stabilization of the patient, symptomatic treatment, and, if appropriate, the use of specific antidotes. Continuous monitoring of vital signs and clinical status is recommended to ensure patient safety and effective management of the overdose situation.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222 in the event of an overdose. It is important to inform patients that laxative products should not be used for longer than one week unless specifically directed by a physician.

Patients should be instructed to discontinue use and consult a doctor if they experience rectal bleeding or if there is no bowel movement after using the product, as these symptoms may indicate a serious medical condition. Providers should emphasize the importance of adhering to the maximum recommended daily dosage and not exceeding it within a 24-hour period.

Additionally, healthcare providers should encourage patients to consult with a doctor prior to use if they have any of the following conditions: kidney disease, a magnesium-restricted diet, a sodium-restricted diet, stomach pain, nausea, vomiting, or if they have noticed a sudden change in bowel habits lasting more than one week. It is also advisable for patients to speak with a doctor or pharmacist before using the product if they are currently taking any prescription medications.

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which are essential for identification and inventory management. It is crucial to store the product within the temperature range of 46ºF to 86ºF (8ºC to 30ºC). Refrigeration is not permitted, and the product must be protected from excessive heat and freezing conditions to maintain its integrity.

Healthcare professionals should ensure that any unused product is discarded within 24 hours of opening the bottle to prevent potential degradation or contamination. Proper adherence to these storage and handling guidelines is essential for ensuring the product's efficacy and safety.

Additional Clinical Information

The medication is administered orally. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. It is essential to keep the medication out of reach of children, and in the event of an overdose, patients should seek medical assistance or contact a Poison Control Center immediately at 1-800-222-1222. No further information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Onelax, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)